The Chinese pharmaceutical manufacturer, WuXi Biologics, has announced it will be expanding its operations to Singapore.
The company has confirmed it’s third manufacturing site in less than a month, with a S$80mn (US$60mn) facility in its first Asian city country outside of China.
The contract development and manufacturing organisation (CDMO) aims for the site to employ 150 members of staff when operational.
The facility will feature 4,500l of bioreactor capacity, made up of two 2,000l traditional fed-batch reactors and one 500l perfusion-based continuous processing capabilities.
The site has been designed to manage clinical and small-volume commercial production.
The project has been financial backed the Singapore Economic Development board, who will contribute to the funding.
“We are all very excited to initiate our first overseas Asian site in Singapore to enable local companies and expedite biologics development in Asia,” announced Dr Chris Chen, CEO of WuXi Biologics.
“We are committed to becoming the most comprehensive capability and technology platform in the global biologics industry to enable both local and global partners.”
WuXi Biologics has recently announced it will be developing a biologics facility in Dundalk, Ireland, costing €325mn ($392mn).